Tuesday, 23 June 2026 edition — The Vital Record

In brief

• Biotech Business AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash The deal centers on zumilokibart, a long-acting anti-IL-13 antibody in late-stage development for atopic dermatitis and asthma, as AbbVie deepens its post-Humira immunology portfolio.
• Biotech Business Definium's Psychedelic-Derived Pill Clears Key Hurdle in Depression, Sending Stock Surging 47% DT120, a single-dose lysergide tablet, beat placebo by 8.1 points on a validated depression scale in Phase 3 — a first for a psychedelic-class compound in a broad MDD pivotal trial — though a second study and FDA review lie ahead.
• FDA & Regulatory FDA Puts Drug Rejection Letters on the Public Record—In Real Time Commissioner Makary's 'radical transparency' push ends decades of confidentiality for complete response letters, with cytisinicline's manufacturing-only CRL arriving as one of the first under the new regime—and a Covington & Burling petition arguing the whole policy may be unlawful.
• Research The Lancet Flags Exenatide–Parkinson's Phase 3 Trial With Expression of Concern Editors have signaled unresolved questions about a high-profile GLP-1 trial — but an Expression of Concern is not a retraction, and no disease-modifying therapy for Parkinson's has emerged to replace the hope it carried.
• Digital Health & AI Colorado's Landmark AI Law Hits Its Enforcement Date — In Name Only SB 24-205 nominally takes effect June 30, but a federal court stay, a DOJ intervention, and a signed replacement law have put actual enforcement on hold indefinitely.
• Clinical Trials Biohaven's IgG Degrader Takes on Graves' Disease in First Phase 3 Trial of This Novel Antibody-Depleting Approach BHV-1300 targets the autoantibody root cause of Graves' hyperthyroidism — asking whether patients can reach normal thyroid function without antithyroid drugs by Week 26.